Biocon inches up on starting clinical study of Itolizumab for Ulcerative Colitis in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Biocon is currently trading at Rs. 271.70, up by 0.05 points or 0.02% from its previous closing of Rs. 271.65 on the BSE.
The scrip opened at Rs. 272.05 and has touched a high and low of Rs. 273.65 and Rs. 269.50 respectively. So far 58465 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 258.30 on 17-Oct-2022.
Last one week high and low of the scrip stood at Rs. 277.30 and Rs. 265.50 respectively. The current market cap of the company is Rs. 32782.38 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.55% and 15.81% respectively.
Biocon has started clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.
Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialized in handling UC cases. The first patient who intended to participate in the study was screened on December 1, 2022.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
